Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

EiPLA

Add links
From Wikipedia, the free encyclopedia

EiPLA
Clinical data
Other namesEiPLA; Ethylisopropyllysergamide; N-Ethyl-N-isopropyllysergamide; Lysergic acid ethylisopropylamide
Routes of
administration		Oral[1]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • (6aR,9R)-N-ethyl-7-methyl-N-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC21H27N3O
Molar mass337.467 g·mol−1
3D model (JSmol)
  • CCN(C(C)C)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=1S/C21H27N3O/c1-5-24(13(2)3)21(25)15-9-17-16-7-6-8-18-20(16)14(11-22-18)10-19(17)23(4)12-15/h6-9,11,13,15,19,22H,5,10,12H2,1-4H3/t15-,19-/m1/s1
  • Key:JLPRDEGOBAGMHN-DNVCBOLYSA-N

EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2][3][1] It is an isomer of ETH-LAD.[1]

Use and effects

[edit]

EiPLA has been identified in blotter containing doses of 86 to 97 μg base equivalent per tab.[1] Blotter containing 200 μg per tab has also been described.[1] Anecdotal reports suggest that EiPLA produces psychedelic effects but is less potent than LSD.[1]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

In drug discrimination tests in rodents, EiPLA was found to have approximately half the potency of LSD.[2][3][1]

Chemistry

[edit]

Analogues

[edit]

Analogues of EiPLA include MiPLA, LAMPA (MPLA), EPLA, EcPLA, and ETFELA, among others.[1][4]

History

[edit]

EiPLA was first described in the scientific literature by David E. Nichols and colleagues by at least 1994.[2] It appears to have emerged as a novel designer drug by 2019.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 Brandt SD, Kavanagh PV, Westphal F, Pulver B, Schwelm HM, Stratford A, et al. (February 2024). "Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N6 -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)". Drug Testing and Analysis. 16 (2): 187–198. doi:10.1002/dta.3530. PMID 37321559.
  2. 1 2 3 Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (March 1994). "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior. 47 (3): 667–673. doi:10.1016/0091-3057(94)90172-4. PMID 8208787.
  3. 1 2 Nichols DE (October 2018). "Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)". ACS Chemical Neuroscience. 9 (10): 2331–2343. doi:10.1021/acschemneuro.8b00043. PMID 29461039.
  4. ↑ Wachełko O, Nowak K, Tusiewicz K, Zawadzki M, Szpot P (January 2025). "A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies". Analyst. 150 (2): 290–308. doi:10.1039/d4an01361a. PMID 39636448.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=EiPLA&oldid=1339606428"